In looking at the long term dividend history, on average over the past five years, Johnson & Johnson has paid out $2.422 to shareholders annually. Similarly, the revenue expectations of $17.47 billion also exceed the consensus estimate of $17.45 billion by a small margin.
Advertisement
Analysts’ estimates that the company will report net income of $4.097 billion for 3QFY15, which would signify a fall of 4.54% year-over-year (YoY) as compared to net income of $4.29 billion reported in 3QFY14. The whisper number is $1.48, three cents ahead of the analysts’ estimate and showing a few confidence from the WhisperNumber community.
As of Monday’s close, J&J shares have fallen 8.2% so far this year.
The company said its adjusted profit was $1.49 per share.
J&J shares were up 1.31% at $97.25 in pre-market trading after the announcement. The 52-week low of the share price is at $81.79.
Robert Wood Johnson Foundation holds 99.91% of its portfolio in Johnson & Johnson for 13.00 million shares.
Excluding fluctuations foreign exchange rates, which hurt revenue because of the stronger US dollar, sales would have increased 0.8 percent, J&J said.
Advertisement
The repurchase would take away almost 104 million shares of the company’s outstanding shares, according to Thomson Reuters calculations. The Firm is engaged in the research and development, manufacture and sale of a range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products in virtually all countries throughout the world. The Company’s primary focus is products linked to human health and wellbeing. The Company’s subsidiary companies operate 134 production facilities occupying approximately 21.5 million square feet of floor space.
